Boston Scientific (NYSE: BSX) CFO logs RSU conversions and tax share moves

Q: What types of securities are involved in Jonathan Monson’s Boston Scientific (BSX) Form 4 filing?

The filing involves restricted stock units and resulting common stock . RSUs were converted into common shares at a stated price of $0.0000 per share, and portions of the issued common stock were then used to satisfy tax obligations at a price of $74.73 per share.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Boston Scientific EVP and CFO Jonathan Monson reported a series of equity award transactions. On February 13, 14 and 16, 2026, restricted stock units were converted into common stock in blocks of 1,766, 1,058 and 990 shares at $0.0000 per share, reflecting vesting of prior grants. On each date, portions of the resulting common shares (788, 470 and 440 shares) were disposed of at $74.73 per share to satisfy tax obligations through share withholding. Following these transactions, Monson directly owned 37,986 shares of Boston Scientific common stock.

Insider Trade Summary

3,814 shares exercised/converted

Mixed 9 txns

Insider Monson Jonathan

Role EVP and CFO

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	990	$0.00	--
Exercise	Common Stock	990	$0.00	--
Tax Withholding	Common Stock	440	$74.73	$33K
Exercise	Restricted Stock Units	1,058	$0.00	--
Exercise	Common Stock	1,058	$0.00	--
Tax Withholding	Common Stock	470	$74.73	$35K
Exercise	Restricted Stock Units	1,766	$0.00	--
Exercise	Common Stock	1,766	$0.00	--
Tax Withholding	Common Stock	788	$74.73	$59K

Holdings After Transaction: Restricted Stock Units — 0 shares (Direct); Common Stock — 38,426 shares (Direct)

Footnotes (1)

Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant.

Form 4 Insider Transactions: What Each Field Means →

02/18/2026 - 05:58 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Monson Jonathan

(Last)

(First)

(Middle)

300 BOSTON SCIENTIFIC WAY

(Street)

MARLBOROUGH

01752-1234

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
BOSTON SCIENTIFIC CORP [ BSX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP and CFO

3. Date of Earliest Transaction (Month/Day/Year)
02/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/13/2026		M		1,766	A	$0.0000⁽¹⁾	37,636	D
Common Stock	02/13/2026		F		788	D	$74.73	36,848	D
Common Stock	02/14/2026		M		1,058	A	$0.0000⁽¹⁾	37,906	D
Common Stock	02/14/2026		F		470	D	$74.73	37,436	D
Common Stock	02/16/2026		M		990	A	$0.0000⁽¹⁾	38,426	D
Common Stock	02/16/2026		F		440	D	$74.73	37,986	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽¹⁾	02/13/2026		M			1,766	⁽²⁾	02/13/2029⁽²⁾	Common Stock	1,766	$0.0000	5,300	D
Restricted Stock Units	⁽¹⁾	02/14/2026		M			1,058	⁽³⁾	02/14/2027⁽³⁾	Common Stock	1,058	$0.0000	1,058	D
Restricted Stock Units	⁽¹⁾	02/16/2026		M			990	⁽⁴⁾	02/16/2026⁽⁴⁾	Common Stock	990	$0.0000	0.0000	D

Explanation of Responses:

1. Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

2. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant.

3. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant.

4. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant.

	/s/ Susan Thompson, Attorney-in-Fact	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Boston Scientific (BSX) CFO Jonathan Monson report?

Jonathan Monson reported conversions of restricted stock units into Boston Scientific common stock and related tax-withholding share dispositions. Over February 13–16, 2026, several RSU blocks vested into shares, with a portion of those shares delivered back to cover tax obligations.

How many Boston Scientific (BSX) shares does CFO Jonathan Monson own after these Form 4 transactions?

After the reported transactions, Jonathan Monson directly owns 37,986 shares of Boston Scientific common stock. This figure reflects RSU conversions into shares and share dispositions used to satisfy tax liabilities associated with the vesting events disclosed in the Form 4.

What types of securities are involved in Jonathan Monson’s Boston Scientific (BSX) Form 4 filing?

The filing involves restricted stock units and resulting common stock. RSUs were converted into common shares at a stated price of $0.0000 per share, and portions of the issued common stock were then used to satisfy tax obligations at a price of $74.73 per share.

Were Boston Scientific (BSX) shares sold by CFO Jonathan Monson on the open market?

The Form 4 shows code F transactions described as “Payment of exercise price or tax liability by delivering securities.” This indicates shares were disposed of to cover tax obligations related to vesting, rather than being characterized as open-market purchases or sales in the disclosure.

On what dates did Boston Scientific (BSX) CFO Jonathan Monson have RSU conversions?

RSU conversions into Boston Scientific common stock occurred on February 13, 2026, February 14, 2026, and February 16, 2026. On each date, restricted stock units were converted into common shares, with a portion of those shares then delivered to satisfy associated tax liabilities.

What prices are disclosed in Jonathan Monson’s Boston Scientific (BSX) Form 4 transactions?

The RSU conversions list a transaction price of $0.0000 per share for common stock issued from restricted stock units. The tax-withholding dispositions show a transaction price of $74.73 per share for the common shares used to pay the related tax liabilities described in the filing.